Sobrera Pharma

Executive Summary

Sobrera Pharma is a Swedish biopharmaceutical company founded in 2018, dedicated to developing novel small-molecule therapies for addiction and related mental health disorders. Its lead program is a Phase II combination therapy for Alcohol Use Disorder (AUD), an area with significant unmet medical need and limited effective treatment options. The company aims to reduce alcohol consumption and mitigate associated health and societal damages. Based in Stockholm and Gothenburg, Sobrera leverages its deep expertise in neuroscience to advance a pipeline that addresses the neurobiological underpinnings of addiction. While still privately held and without disclosed financials, the company's focus on a high-prevalence condition positions it for potential growth if clinical data prove positive.

Upcoming Catalysts (preview)

• Q3 2027Phase II topline data readout for AUD combination therapy30% success
• Q4 2026Private financing round to advance pipeline60% success